DISEASE INDICATIONS: Cystic Fibrosis

MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Kalydeco (ivacaftor) is a medication that is approved for the treatment of cystic fibrosis (CF) in patients aged 4 months and above who possess at least one mutation in their CF gene that is receptive to Kalydeco.